BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34251713)

  • 21. MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of programmed death ligand-1 expression.
    Fan Y; Che X; Hou K; Zhang M; Wen T; Qu X; Liu Y
    Exp Cell Res; 2018 Dec; 373(1-2):180-187. PubMed ID: 30367831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
    Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
    Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
    Zhang T; Yu H; Dai X; Zhang X
    Front Immunol; 2022; 13():971428. PubMed ID: 35958549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice.
    Dimitrov V; Bouttier M; Boukhaled G; Salehi-Tabar R; Avramescu RG; Memari B; Hasaj B; Lukacs GL; Krawczyk CM; White JH
    J Biol Chem; 2017 Dec; 292(50):20657-20668. PubMed ID: 29061851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.
    Sato H; Niimi A; Yasuhara T; Permata TBM; Hagiwara Y; Isono M; Nuryadi E; Sekine R; Oike T; Kakoti S; Yoshimoto Y; Held KD; Suzuki Y; Kono K; Miyagawa K; Nakano T; Shibata A
    Nat Commun; 2017 Nov; 8(1):1751. PubMed ID: 29170499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
    Liu Y; Li X; Zhang H; Zhang M; Wei Y
    Oncogene; 2021 Mar; 40(12):2230-2242. PubMed ID: 33649535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
    Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
    J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorting nexin 6 interacts with Cullin3 and regulates programmed death ligand 1 expression.
    Ghosh C; Xing Y; Li S; Hoyle RG; Sun M; Li J; Sun Y
    FEBS Lett; 2021 Oct; 595(20):2558-2569. PubMed ID: 34510437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence.
    Muranushi R; Araki K; Yokobori T; Chingunjav B; Hoshino K; Dolgormaa G; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Harimoto N; Shimoda Y; Sano R; Oyama T; Saeki H; Shirabe K
    Cancer Sci; 2021 Aug; 112(8):3314-3323. PubMed ID: 34080242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer cells promote CD169
    Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
    Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
    Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
    Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
    Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
    Yoshino H; Sato Y; Nakano M
    Curr Issues Mol Biol; 2021 May; 43(1):153-162. PubMed ID: 34069326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells.
    Song N; Bai M; Che X; Li Z; Jing W; Li C; Teng Z; Qu X; Liu Y
    Med Oncol; 2020 Apr; 37(5):47. PubMed ID: 32277292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 40. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.